Mode
Text Size
Log in / Sign up
N/A N=102 Randomized Double-blind Treatment

ANI Versus Standard Care in Surgical Patients Receiving Balanced Sevoflurane-Fentanyl Anesthesia

Acute Pain

Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: The Incidence of Severe Postoperative Pain — 49; 53 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
ANI-guided opioid administration (Device); Standard opioid administration (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Texas Southwestern Medical Center
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
The Incidence of Severe Postoperative Pain
49; 53
SECONDARY
The Incidence of Pain Medication Use
224.1; 294.4
SECONDARY
The Incidence of Postoperative Nausea/Vomiting in Post-anesthesia Care Unit (PACU)
0; 0
SECONDARY
The Incidence of Minimal Pain
12; 22

Summary

This study aims to be a randomized, controlled study of ANI-guided opioid administration versus standard clinical practice in surgical patients undergoing general anesthesia with balanced sevoflurane-fentanyl. Patients will be randomly assigned to 2 groups- ANI vs. standard care. The intraoperative and postoperative management of all patients will be standardized by protocol. The PACU nurses and postop assessor will be blinded as to which group the patient is in.

Eligibility Criteria

Inclusion Criteria

  • 18-75 years old
  • ASA 1-2
  • BMI 19-35 kg/m2
  • Patients undergoing surgery with general anesthesia with sevoflurane- fentanyl
  • Planned abdominal or spinal surgery lasting 1-3 hours
  • Willing and able to consent in English or Spanish
  • No current history of advanced pulmonary or cardiovascular disease

Exclusion Criteria

  • Age less than 18 or older than 75
  • Patient does not speak English or Spanish
  • Patient refusal
  • Monitored anesthesia care (MAC) or regional anesthesia planned
  • Pregnant or nursing women
  • "Stat" (emergent) cases
  • ECG rhythm other than regular sinus rhythm
  • Implanted pacemakers
  • On antimuscarinic agents, alpha 2 agonists, antiarrhythmics, or beta blockers
  • Presence of pacemaker
  • Autonomic nervous system disorder
  • Use of chronic opioids
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03684590). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search